Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
White matter changes associated with antipsychotic treatment in first-episode psychosis.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- White Matter Microstructure in Individuals With and At Risk for Bipolar Disorder: Evidence for an Endophenotype From a Voxel-Based Meta-analysis.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2020Pooled it
- Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features.Molecular psychiatry · 2023Trial
- A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.Psychiatry research. Neuroimaging · 2021Trial
- Trial
- Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2019Trial
- N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial.Translational psychiatry · 2018Trial
- Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication.Human brain mapping · 2015Trial
- Chronic schizophrenia versus Alzheimer's disease: neuroimaging perspectives on the late-life course of schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Central Obesity-related Brain Alterations Predict Cognitive Impairments in First Episode of Psychosis.Schizophrenia bulletin · 2026Observational
- Risperidone reduces individualized morphometric similarity deviation in schizophrenia and associates with cortical transcriptomic patterns.Schizophrenia (Heidelberg, Germany) · 2026Article
- Psychotic-Like Experiences and White Matter Microstructure: A Fixel-Based Analysis Approach With Robust Replication Across Two Cohorts.Human brain mapping · 2025Article
- White matter microstructural abnormalities related to emotional dysfunction and childhood trauma characterize adolescents with borderline personality disorder.Brain imaging and behavior · 2025Article
- Investigation of brain white matter and social cognition in schizophrenia and schizotypal personality disorder using neurite orientation dispersion and density imaging.Molecular psychiatry · 2025Article
- White matter abnormalities of the frontal-striatal-thalamic circuit in individuals with attenuated positive symptom syndromes: a probabilistic tractography study.Schizophrenia (Heidelberg, Germany) · 2025Article
- Along-tract white matter abnormalities and their clinical associations in recent-onset and chronic schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Transcallosal white matter and cortical gray matter variations in autistic adults aged 30-73 years.Molecular autism · 2025Article
- Distinguished Frontal White Matter Abnormalities Between Psychotic and Nonpsychotic Bipolar Disorders in a Pilot Study.Brain sciences · 2025Article
- A narrative literature review of white matter microstructure in individuals at clinical high risk for psychosis.Psychoradiology · 2025Review
- MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone.Frontiers in psychiatry · 2025Review
- Tract-based analyses of white matter in schizophrenia, bipolar disorder, aging, and dementia using high spatial and directional resolution diffusion imaging: a pilot study.Frontiers in psychiatry · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Second-generation antipsychotics are utilized extensively in the treatment of psychotic disorders and other psychiatric conditions, but the effects of these medications on human brain white matter are not well understood. We thus investigated the effects of second-generation antipsychotics on white matter integrity using tract-based spatial statistics in patients experiencing a first episode of psychosis with little or no prior antipsychotic exposure, and how potential changes were associated with metabolic side effects. Thirty-five (26 men/9 women) patients experiencing a first episode of psychosis received diffusion tensor imaging (DTI) exams, clinical assessments, and provided fasting blood samples at the onset of antipsychotic treatment, and then again after 12 weeks of treatment with either risperidone or aripiprazole in a double-blind randomized clinical trial. In addition, 35 (26 men/9 women) healthy volunteers received DTI exams at a baseline time point and then after 12 weeks. Patients demonstrated significant (p<0.05; family-wise error corrected) fractional anisotropy reductions within the parietal and occipital white matter following antipsychotic treatment. Greater overall fractional anisotropy reduction was significantly correlated with greater increases in low-density lipoprotein. There were no significant fractional anisotropy increases among patients following treatment. Moreover, healthy volunteers did not demonstrate either significant increases or decreases in fractional anisotropy across a comparable 12-week interval. The use of antipsychotics may be associated with a subtle loss of white matter integrity that is related to greater side effects, thus raising potentially important considerations regarding risk/benefit in their usage. Limitations of the current study, however, include a prior history of substance use among patients and our inability to exclude the possibility of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.